{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidcrgomx5cehk7bqzmmlbr2pqwnpfg3vg5fxeqaf4sbb55ep3nf54",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mntn372eax62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig2dqgtmvjonunx3h2ccwrspdgxszq5gfs4qzpyinoy6w32kdi4ii"
    },
    "mimeType": "image/jpeg",
    "size": 156242
  },
  "path": "/2026/06/08/pancreatic-cancer-combination-tango-therapeutics-revolution-medicines-vopimetostat-daraxonrasib/?utm_campaign=rss",
  "publishedAt": "2026-06-08T11:55:45.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "Cancer",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.",
  "title": "STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate",
  "updatedAt": "2026-06-08T12:35:59.000Z"
}